A novel clinical study conducted on Arjuna Natural’s newly debuted Somin-On ashwagandha extract has found that the Ayurvedic herb can enhance cognitive function and memory retention in adults with MCI.
The nutraceutical is standardised to 2% sominone — a withanolide touted for its ability to repair damaged nerve cells, promote neurite outgrowth and reduce oxidative stress — and has been shown to enhance attention, improve cognitive performance & reduce the impact of cognitive impairment.
These findings add to the clinical evidence highlighting ashwagandha's benefits, with studies revealing its potential in managing postmenopausal symptoms, stress and anxiety, mood, the immune system and joint pain.
However, there is a mixed opinion on ashwagandha's safety throughout the western world, with Canada recently affirming its safety, while Denmark has banned its use in dietary supplements.
To find out more about the study's findings and the wide-spanning potential of ashwagandha-derived withanolides in healthy ageing and cognition, NBR chatted with Arjuna Natural's Joint Managing Director, Dr Benny Antony.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.